Transgender hormone therapy (female-to-male) to individuals taking bioidentical hormones in the form of testosterone (including esters) and do not apply to those taking synthetic AAS (e.g., nandrolone) or dihydrotestosterone. Transgender hormone therapy (female-to-male) Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine (or androgynous) to masculine. It is one of two types of transgender hormone therapy (the other being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people
Male accessory gland infection a more complicated form of MAGI, such as involving more than one site, than those with normal levels. Potential complications include: These complications can result in sexual dysfunction and male subfertility. Male accessory gland infection Male Accessory Gland Infection (MAGI), also known as Male Accessory Gland Inflammation, is a condition with signs of inflammation involving one or more sites in the male genital tract. Diagnosis is made according to parameters defined by the World Health Organization, and it is particularly made in relation to infectious or inflammatory causes of male infertility. Although it is usually caused by infection spreading from